S. Constantinescu

发表

A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline

L. Varghese, J. Martínez-López, E. Sebastián, 2021, Leukemia.

Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

C. Pecquet, A. Shiau, A. Dusa, 2019, The Journal of allergy and clinical immunology.

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders

W. Vainchenker, I. Plo, C. Marty, 2018, F1000Research.

Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix

A. Shiau, A. Dusa, Amir Motamedi, 2016, The Biochemical journal.

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.

C. Pecquet, E. Solary, W. Vainchenker, 2013, Blood.

JAK/STAT signaling in hematological malignancies

W. Vainchenker, S. Constantinescu, W Vainchenker, 2013, Oncogene.

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

W. Vainchenker, A. Dusa, S. Constantinescu, 2008, Seminars in cell & developmental biology.

An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

W. Vainchenker, J. Staerk, C. Lacout, 2006, Blood.

Erythropoietin and Erythropoietin Receptor: History, Structure, Interactions, and Intracellular Signal Transduction

S. Ghaffari, S. Constantinescu, 2004 .

Extracellular Domain N-Glycosylation Controls Human Thrombopoietin Receptor Cell Surface Levels

R. Albu, S. Constantinescu, 2011, Front. Endocrin..

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

W. Vainchenker, C. James, V. Ugo, 2005, Trends in molecular medicine.

Activating mutations in human acute megakaryoblastic leukemia.

A. Baruchel, W. Vainchenker, O. Bernard, 2008, Blood.

Targets in MPNs and potential therapeutics.

C. Pecquet, C. Diaconu, V. Havelange, 2022, International review of cell and molecular biology.

Functional Consequences of Mutations in Myeloproliferative Neoplasms

W. Vainchenker, S. Constantinescu, G. Levy, 2021, HemaSphere.

Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

F. Pasquier, E. Solary, W. Vainchenker, 2020, Oncogene.

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.

S. Kubicek, R. Kralovics, R. Lesyk, 2020, Blood.

The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications

W. Vainchenker, I. Plo, L. Varghese, 2019, Expert review of hematology.

Recent advances in understanding myelofibrosis and essential thrombocythemia

W. Vainchenker, I. Plo, S. Constantinescu, 2016, F1000Research.

JAK inhibitors in myeloproliferative neoplasms

S. Constantinescu, L. Knoops, S. Constantinescu, 2011 .

JAK2, the JAK2 V617F mutant and cytokine receptors.

W. Vainchenker, J. Staerk, A. Dusa, 2007, Pathologie-biologie.

Oncogenic mechanisms in myeloproliferative disorders

W. Vainchenker, C. James, F. Delhommeau, 2006, Cellular and Molecular Life Sciences CMLS.

Review Oncogenic mechanisms in myeloproliferative disorders

W. Vainchenker, C. James, F. Delhommeau, 2006 .

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.

W. Vainchenker, S. Constantinescu, 2005, Hematology. American Society of Hematology. Education Program.

A biological profile for diagnosis and outcome of COVID-19 patients

E. Coche, P. Saussoy, J. Yombi, 2020, Clinical chemistry and laboratory medicine.

An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.

C. Pecquet, G. Leverger, W. Vainchenker, 2016, Blood.

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Mark S. Anderson, Chun Jimmie Ye, Gabriela K. Fragiadakis, 2022, Science immunology.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

E. Solary, W. Vainchenker, L. Knoops, 2014, Leukemia.

JAK inhibitors and COVID-19

P. Guglielmelli, P. Langmuir, S. Constantinescu, 2022, Journal for ImmunoTherapy of Cancer.

CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag.

N. Balayn, W. Vainchenker, R. Favier, 2021, Blood.

Mpl and thrombocytosis: levels matter.

S. Constantinescu, 2009, Blood.

Ligand-independent Thrombopoietin Mutant Receptor Requires Cell Surface Localization for Endogenous Activity*

W. Vainchenker, C. Lacout, J. Villeval, 2009, Journal of Biological Chemistry.

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

C. Pecquet, W. Vainchenker, H. Raslova, 2016, Blood.

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

C. Pecquet, P. Courtoy, W. Vainchenker, 2016, Blood.

Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.

M. Hochberg, F. Pasquier, E. Solary, 2021, Blood.

Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms

W. Vainchenker, H. Raslova, M. Bonamino, 2021, HemaSphere.

Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN

W. Vainchenker, H. Raslova, J. Villeval, 2020, Nature Communications.

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

D. Vertommen, C. Pecquet, W. Vainchenker, 2019, Blood.

Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice

W. Vainchenker, H. Raslova, J. Villeval, 2018, Oncogene.

Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.

C. Pecquet, A. Shiau, M. Choong, 2018, Methods in molecular biology.

The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation.

L. Knoops, D. Selleslag, S. Constantinescu, 2008, Blood.

Constitutive Activation and Oncogenicity Are Mediated by Loss of Helical Structure at the Cytosolic Boundary of the Thrombopoietin Receptor

C. Pecquet, Steven O. Smith, S. Constantinescu, 2022, bioRxiv.

Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms

C. Pecquet, S. Constantinescu, J. Defour, 2016, Leukemia.

Orientation‐specific signalling by thrombopoietin receptor dimers

C. Pecquet, W. Vainchenker, J. Staerk, 2011, The EMBO journal.

Telomere-induced senescence increases aberrant intraneuronal amyloid-β accumulation by impairing autophagy in a mouse model of Alzheimer’s disease

P. Kienlen-Campard, A. Decottignies, S. Constantinescu, 2022, bioRxiv.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

J. Soulier, S. Demeyer, K. Jacobs, 2018, Blood.

The 2 faces of ERK2 in MPNs.

V. Havelange, S. Constantinescu, 2022, Blood.

Degrading JAK2 in ALL by ruxolitinib-based PROTACs

C. Pecquet, S. Constantinescu, 2021 .

New mutations and pathogenesis of myeloproliferative neoplasms.

W. Vainchenker, O. Bernard, F. Delhommeau, 2011, Blood.

Stem cell generation and choice of fate: role of cytokines and cellular microenvironment

S. Constantinescu, 2000, Journal of cellular and molecular medicine.

Role of tyrosine kinases and phosphatases in polycythemia vera.

W. Vainchenker, Z. Zhao, N. Casadevall, 2005, Seminars in hematology.

CLINICAL IMPLICATIONS OF JAK2 MUTATIONS IN MYELOPROLIFERATIVE DISORDERS

S. Constantinescu, L. Knoops, A. Ferrant, 2008, Acta Clinica Belgica.

Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia.

N. Ben-Tal, M. Muckenthaler, J. Twizere, 2014, Blood.

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.

F. Sigaux, J. Soulier, T. Haferlach, 2011, Blood.

PTPN 2 negatively regulates oncogenic JAK 1 in T-cell acute lymphoblastic leukemia

F. Sigaux, J. Soulier, T. Haferlach, 2011 .

Studying severe long COVID to understand post-infectious disorders beyond COVID-19

Mark S. Anderson, P. Gregersen, J. Casanova, 2022, Nature Medicine.

Aberrant signal transduction pathways in myeloproliferative neoplasms

S. Constantinescu, J. Kota, N. Cáceres, 2008, Leukemia.

A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation

F. Pasquier, W. Vainchenker, R. Chaligné, 2010, PLoS biology.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

S. Linnarsson, R. Sandberg, P. Campbell, 2014, Cancer cell.

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition

S. Constantinescu, E. Leroy, 2017, Leukemia.

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations

S. Constantinescu, X. Cahu, 2015, Current Hematologic Malignancy Reports.

Differential STAT5 Signaling by Ligand-dependent and Constitutively Active Cytokine Receptors*

V. Moucadel, S. Constantinescu, 2005, Journal of Biological Chemistry.

MPL S505C enhances driver mutations at W515 in essential thrombocythemia

I. Rapado, L. Varghese, J. Martínez-López, 2021, Blood Cancer Journal.

Fighting viral diseases and COVID-19 with tools allowing precise prediction of protein structure

S. Constantinescu, 2021, Romanian Archives of Microbiology and Immunology.

MPL Mutations in Essential Thrombocythemia Uncover A Common Path of Activation with Eltrombopag Dependent on W491.

S. Carillo, Steven O. Smith, L. Varghese, 2020, Blood.

MPL membrane domain sequencing goes deep.

L. Varghese, S. Constantinescu, 2020, Blood.

The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters

Steven O. Smith, S. Constantinescu, E. Leroy, 2019, Leukemia.

The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin

C. Pecquet, L. Varghese, S. Constantinescu, 2017, Front. Endocrinol..

Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines.

P. Tulkens, F. Van Bambeke, P. Sonveaux, 2019, International journal of antimicrobial agents.

Human genetic and immunological determinants of critical COVID-19 pneumonia

Mark S. Anderson, P. Gregersen, J. Casanova, 2022, Nature.

Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands

Irving L. Weissman, Samuel Demharter, Jacob Piehler, 2015, Cell.

Tuning Cytokine Receptor Signaling by Reorienting Dimer Geometry with Surrogate Ligands Graphical

Irving L. Weissman, Samuel Demharter, Jacob Piehler, 2015 .

A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens

S. Constantinescu, 2009, Journal of cellular and molecular medicine.

STAT Signaling by Erythropoietin

V. Moucadel, S. Constantinescu, 2003 .

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

P. Campbell, P. Vyas, E. Papaemmanuil, 2019, Cancer cell.

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis

F. Pasquier, W. Vainchenker, H. Raslova, 2017, Haematologica.

New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia

F. Pasquier, W. Vainchenker, H. Raslova, 2016 .

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer

B. Leyland-Jones, M. Aapro, W. Jelkmann, 2012, British Journal of Cancer.

Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.

C. Pecquet, R. Kralovics, K. Kapralova, 2016, Blood.

Erratum: Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome (Cancer Cell (2019) 36(2) (123–138.e10), (S1535610819302983), (10.1016/j.ccell.2019.06.007))

P. Campbell, P. Vyas, E. Papaemmanuil, 2019 .

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

P. Campbell, P. Vyas, E. Papaemmanuil, 2019, Cancer cell.

Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced Myocarditis

Mark S. Anderson, P. Gregersen, J. Casanova, 2022, Journal of Clinical Immunology.

FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors

I. Macaulay, P. Woll, P. Vyas, 2013, Cell reports.

An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia

W. Vainchenker, N. Debili, S. de Botton, 2009, The Journal of experimental medicine.

JAK/STAT Signalling and Haematological Malignancies

W. Vainchenker, S. Constantinescu, 2015 .

Thrombopoietin receptor is required for the oncogenic function of CALR mutants

C. Pecquet, W. Vainchenker, R. Kralovics, 2016, Leukemia.

Neurobiology of Vascular Dementia

D. Muresanu, B. Popescu, S. Constantinescu, 2011, Journal of aging research.

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

W. Vainchenker, N. Debili, R. Favier, 2016, Blood.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

M. Cazzola, C. Bock, R. Kralovics, 2015, Blood.

JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.

F. Pasquier, E. Solary, W. Vainchenker, 2014, Blood.

Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis

C. Pecquet, W. Vainchenker, R. Kralovics, 2014 .

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation

G. Mazzucchelli, D. Vertommen, C. Pecquet, 2023, Nature Communications.

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

C. Pecquet, W. Vainchenker, R. Kralovics, 2016, Leukemia.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice

O. Abdel-Wahab, E. Solary, W. Vainchenker, 2023, Leukemia.

Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms.

M. Cazzola, D. Vertommen, C. Pecquet, 2022, Blood.

miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.

C. Pecquet, W. Vainchenker, L. Knoops, 2010, Blood.

Gathering support for critical mass: interleukin 4 receptor signaling requires clustering in endosomes.

S. Constantinescu, 2014, Biophysical journal.

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

M. Cazzola, C. Pecquet, W. Vainchenker, 2018, Blood.

Crispr/Cas9 Engineered 61bp Deletion in the Calr Gene of Mice Leads to Development of Thrombocytosis

C. Pecquet, Y. Achouri, S. Constantinescu, 2016 .

JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.

M. Deininger, N. Cross, J. Prchal, 2019, Blood.

JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5

K. Kapralova, D. Pospíšilová, S. Constantinescu, 2014 .

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

D. Coriu, O. Hermine, C. Diaconu, 2019, Blood.

Introduction to ‘A special spotlight review series on BCR–ABL-negative myeloproliferative neoplasms’

A. Tefferi, S. Constantinescu, 2008, Leukemia.

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

S. Constantinescu, E. Leroy, 2017, Leukemia.

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.

C. Pecquet, P. Coulie, S. Lucas, 2022, Blood.

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Mark S. Anderson, P. Gregersen, R. Nussbaum, 2021, Science Immunology.

Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency

Laura E. Covill, P. Gregersen, J. Casanova, 2022, The Journal of experimental medicine.

The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters

Steven O. Smith, S. Constantinescu, E. Leroy, 2019, Leukemia.

Stemness, fusion and renewal of hematopoietic and embryonic stem cells

S. Constantinescu, S. Constantinescu, 2003, Journal of cellular and molecular medicine.

Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation

C. Pecquet, S. Constantinescu, A. Green, 2014, Oncogene.

Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?

V. Havelange, S. Constantinescu, 2023, American journal of hematology.

Differential Impact of Interferon Alpha on JAK2V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

E. Solary, W. Vainchenker, H. Raslova, 2018, Blood.

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.

C. Pecquet, P. Saussoy, Olga Babosova, 2018, Blood.

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis

N. Cross, S. Constantinescu, Y. Hoade, 2017, Leukemia.

Open Peer Review Recent Advances in Understanding Myelofibrosis and Essential Thrombocythemia [version 1; Referees: 2 Approved] Referee Status

W. Vainchenker, A. Vannucchi, S. Méndez-Ferrer, 2022 .

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers

C. Pecquet, J. Staerk, Steven O. Smith, 2023, eLife.

Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia.

N. Ben-Tal, M. Muckenthaler, J. Twizere, 2014, Blood.

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.

C. Pecquet, E. Solary, W. Vainchenker, 2013, Blood.

MYELOID NEOPLASIA Impact of isolated germline JAK2V617I mutation on human hematopoiesis